Novartis will be presenting more detailed results from its phase 3 studies (HAWK and HARRIER) of brolucizumab (RTH258) vs. aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) at the upcoming annual meeting of the American Academy of Ophthalmology (AAO) on November 10 in New Orleans.
HAWK and HARRIER are the first and only global head-to-head trials in patients with nAMD to prospectively demonstrate efficacy with a prespecifed injection interval of 12 weeks. A potential new therapy that may enable longer intervals between treatments, while also maintaining vision, would help to significantly reduce the current treatment burden on patients and their caregivers.
In June, Novartis reported topline results from HAWK and HARRIER, noting that brolucizumab met the primary and secondary efficacy endpoints in the two studies. RTH258 demonstrated long-lasting efficacy versus aflibercept. Furthermore, a majority of patients, 57% (HAWK) and 52% (HARRIER), were maintained exclusively on a q12w (every 12 week) interval immediately following the loading phase through week 48. These results demonstrated that brolucizumab has the potential to reduce the frequency of eye injections, while providing excellent visual outcomes in this difficult-to-treat disease, according to Novartis.
AAO Presentation Details: November 10, 4:51 p.m. ET: HAWK & HARRIER: 48–week Results Of 2 Multi-Centered, Randomized, Double-Masked Trials of Brolucizumab Versus Aflibercept For Neovascular AMD Pravin U. Dugel, MD; Great Hall, Ernest N. Morial Convention Center